Back to Bills
HOUSE-BILL 4273119th Congress

HOUSE-BILL 4273: H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments

Introduced: July 2, 2025
Status: Reported by Committee
R.for.R

AI-Powered Summary

Generated by AI Analysis

HOUSE-BILL 4273 aims to amend the Federal Food, Drug, and Cosmetic Act to streamline the user fee program for over-the-counter (OTC) monograph drugs, thereby enhancing consumer access to safe and effective medications without a prescription. The legislation addresses major themes such as healthcare access, regulatory efficiency, and market competition. Key provisions include the establishment of user fees for OTC drugs, requirements for the FDA to publish fee amounts and adjustments for transparency, and sunset provisions for periodic review and reauthorization of the fee program. Implementation will require the FDA to adjust its regulatory processes to accommodate the new fee structure, with a timeline for reviews and potential adjustments outlined in the bill. Potential impacts include improved access to OTC medications, concerns about the impact of fees on smaller manufacturers and competition, and implications for public trust in the FDA's regulatory practices, all of which could affect consumer choice and health outcomes.

Demographic Impact Analysis

AI Demographics Analysis

Summary

Overall Constitutional Implications

The bill's implementation of user fees for OTC medications could create barriers to access, particularly for economically disadvantaged groups, raising serious equal protection concerns under the 14th Amendment. The potential for increased costs may limit access to essential healthcare products, which is a fundamental aspect of individual rights.

Key Individual Rights Affected

  • Right to Health
  • Equal Protection under the Law

Constitutional Provisions

  • 14th Amendment - Equal Protection Clause
  • Commerce Clause

Potential Constitutional Challenges

The bill may face challenges based on its disproportionate impact on low-income individuals and marginalized communities, potentially violating the Equal Protection Clause. Additionally, there may be arguments regarding the extent of federal regulation over health products and its implications for state rights.

Summary

HOUSE-BILL 4273 aims to enhance the safety and efficacy of OTC drugs through a user fee program, but it risks infringing upon the equal protection rights of individuals, particularly those from low-income backgrounds. The financial burden imposed by user fees could limit access to essential medications, raising significant constitutional concerns regarding equity in healthcare access.

Constitutional Analysis

R.for.R

This bill has been analyzed for constitutional compliance using AI-powered analysis of constitutional principles and precedents.

Analysis generated using AI-powered review of constitutional principles and legal precedents.

Take Action

Text 50409

💡 How to use:

These links will start a conversation with ResistBot. When prompted, mention H.R. 4273 to reference this bill.

Contact Your Representatives

Write to YOUR elected officials about this bill

Rate This Bill

Sign in to save a private rating for this bill and track your civic engagement over time.

Sign In Free

Policy Topics

Timeline

July 2, 2025

Bill Introduced

Current

Reported by Committee

June 12, 2026

Last Updated

Ask the Constitutional AI About This Bill

Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.

Sign In Free to Chat